Published in Health Insurance Week, October 14th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Decision Resources.
Report 1: Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although Sanofi-Aventis's eplivanserin and Actelion's ACT- 078573 will be market leaders by 2016, the insomnia market is not likely to sustain multiple "me-too" drugs that lack definable safety or efficacy advantages.
The new Pharmacor report Insomnia finds that the 5-HT2 antagonist eplivanserin and the orexin receptor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Insurance Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.